Decode Genetics news from FierceBioResearcher
NewsALSO NOTED: Genetic mutation explains beta blocker failure; CytImmune lauded for nanotech research;New adult stem cell center;
Research Technology An article in the Journal of Alzheimer's Disease presents a detailed characterization of a new drug discovery tool for Alzheimer's disease. It demonstrates that an abnormal form Read more...
deCODE discovers key to a subset of glaucoma
Scientists at Iceland's deCODE Genetics have found the genetic mutation that causes exfoliation glaucoma, a primary cause of blindness in the elderly. A mutation in the LOXL1 gene is apparently the Read more...
| Press ReleasesPositive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack Reykjavik, ICELAND, January 9, 2008 – deCODE genetics (Nasdaq:DCGN) today announced Read more... deCODE Launches deCODEme(TM) REYKJAVIK, Iceland, Nov. 16 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced the launch of deCODEme(TM), a pioneering service that enables individuals to get a detailed look Read more... |
Get more Decode Genetics coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight